Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.72 |
| ▸ | RAB9A | P51151 | 12/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.69 |
| ▸ | HPGD | P15428 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 6/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386825 | 0.90 | NPC1 (0.88) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL2178266 | 0.90 | NPC1 (0.88) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL24295036 | 0.88 | NPC1 (0.84) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL22499602 | 0.86 | NPC1 (0.81) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL2252555 | 0.85 | NPC1 (0.92) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| Benzene SCHEMBL28005151 | 0.84 | NPC1 (1.00) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL105095 | 0.84 | NPC1 (1.00) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL467859 | 0.82 | NPC1 (0.96) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| Potassium SCHEMBL4891434 | 0.82 | NPC1 (0.96) | NPC1RAB9AGAAKDM4EALDH1A1 | |
| SCHEMBL4775610 | 0.82 | NPC1 (0.96) | NPC1RAB9AGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116574063-A | Preparation method of benzimidazole derivative | 厦门医学院 | 2023-08-11 | — | — | CN | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| CN-102046179-B | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2015-01-14 | — | — | CN | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| CN-102046179-A | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2011-05-04 | — | — | CN | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1817805-A1 | USE OF PHENOTHIAZINE-S-OXIDES AND PHENOTHIAZINE -S,S-DIOXIDES IN THE FORM OF MATRIX MATERIALS FOR ORGANIC LIGHT-EMITTING DIODES | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056416-A1 | USE OF PHENOTHIAZINE-S-OXIDES AND PHENOTHIAZINE -S,S-DIOXIDES IN THE FORM OF MATRIX MATERIALS FOR ORGANIC LIGHT-EMITTING DIODES | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | NPC1 472/4885RAB9A 1820/4885GAA 344/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | NPC1 472/4885RAB9A 1820/4885GAA 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.